These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28362701)

  • 41. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
    Bou Samra E; Klein B; Commes T; Moreaux J
    Oncotarget; 2012 Aug; 3(8):824-32. PubMed ID: 22910040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
    Pardee TS
    PLoS One; 2012; 7(8):e43185. PubMed ID: 22905229
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
    Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
    Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
    Marchesini M; Gherli A; Simoncini E; Tor LMD; Montanaro A; Thongon N; Vento F; Liverani C; Cerretani E; D'Antuono A; Pagliaro L; Zamponi R; Spadazzi C; Follini E; Cambò B; Giaimo M; Falco A; Sammarelli G; Todaro G; Bonomini S; Adami V; Piazza S; Corbo C; Lorusso B; Mezzasoma F; Lagrasta CAM; Martelli MP; La Starza R; Cuneo A; Aversa F; Mecucci C; Quaini F; Colla S; Roti G
    Nat Commun; 2024 Jun; 15(1):4739. PubMed ID: 38834613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
    Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
    Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
    Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
    Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A critical role of epigenetic inactivation of miR-9 in EVI1
    Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
    Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.
    Luo H; Li Q; O'Neal J; Kreisel F; Le Beau MM; Tomasson MH
    Blood; 2005 Oct; 106(7):2452-61. PubMed ID: 15972450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.
    Carturan S; Petiti J; Rosso V; Calabrese C; Signorino E; Bot-Sartor G; Nicoli P; Gallo D; Bracco E; Morotti A; Panuzzo C; Gottardi E; Frassoni F; Saglio G; Cilloni D
    Oncotarget; 2016 Nov; 7(45):74082-74096. PubMed ID: 27765915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.
    Zhou JD; Yang L; Zhang YY; Yang J; Wen XM; Guo H; Yao DM; Ma JC; Chen Q; Lin J; Qian J
    Med Oncol; 2015 Jan; 32(1):386. PubMed ID: 25428390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
    Kornblau SM; Thall PF; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating MJ; Kantarjian H; Estey E; Andreeff M
    Clin Cancer Res; 1999 Jul; 5(7):1758-66. PubMed ID: 10430080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.
    Herold T; Metzeler KH; Vosberg S; Hartmann L; Röllig C; Stölzel F; Schneider S; Hubmann M; Zellmeier E; Ksienzyk B; Jurinovic V; Pasalic Z; Kakadia PM; Dufour A; Graf A; Krebs S; Blum H; Sauerland MC; Büchner T; Berdel WE; Woermann BJ; Bornhäuser M; Ehninger G; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
    Blood; 2014 Aug; 124(8):1304-11. PubMed ID: 24923295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center.
    Tiribelli M; Michelutti A; Cavallin M; Di Giusto S; Fanin R; Damiani D
    Turk J Haematol; 2021 Jun; 38(2):119-125. PubMed ID: 33596632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Expression of EVI1 in Bone Marrow of Patients with AML and ALL and Its Correlation with Leukemia Subtyping, Clinical Features and Prognosis of Patients].
    Peng DH; Liu J; Hu HN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1323-1329. PubMed ID: 30295245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.